7:30 am Registration & Coffee
8:25 am Chair’s Opening Remarks
Adenosine’s Role in IO – How Clinical Progress in Adenosine is Shaping the Future of Immunotherapy
8:30 am Leading the Pack – Advanced Clinical Trial Insights to Prepare for the Latest Phases of Development
Synopsis
- Clinical overview of agents targeting adenosine pathway in cancer
- Emerging clinical results with Oleclumab (anti-CD73 mAb)
- What’s the next move for large players and what opportunities could this lead to?
9:00 am Panel Discussion – Targeting the Adenosine Pathway: Perspectives Past, Present & Future
Synopsis
- Discuss the opportunities and rationale for targeting various nodes in the adenosine biology
- Next generation adenosine receptor antagonists and why we believe in them
- Historical perspective of targeting adenosine pathway and how far have we come
9:45 am Speed Networking & Morning Break
Synopsis
A session dedicated to taking advantage of face-to-face networking time. This an exciting opportunity to get an understanding of who else is overcoming similar challenges within the Adenosine space.
10:15 am Interactive Roundtable Activity – Solidifying the Field with a Field-Wide Strategy to Accelerate Progress in Adenosine Therapeutics
Synopsis
Join the discussion as an audience member, share your thoughts, ideas and experiences in small discussion groups to identify solutions to common problems. Get to know fellow participants and grow your network to include decision-makers from industry-leading companies, academics/clinicians from world-renowned institutes and specialists from solution providers across the field. In your groups you will:
- Consider hypotheses about adenosine’s MOA that it would be logical for the field to pursue to fill in the key biological and therapeutic gaps in our knowledge
- Suggest technologies that would support preclinical and clinical development processes
- Discuss how we could collaborate across all sectors effectively to keep the field advancing and on the cutting edge of IO research
- Map these ideas out to form a clear picture of the state of the industry and a plan for progress
Clinical Development Challenges & Rational Strategies For More a Confident Approach to Clinical Trials
11:00 am Panel Discussion – Reviewing Progress in the World of Academic Adenosine Research
Synopsis
Discuss how priorities have changed for the academic research into adenosine and showcase the novel research that is going to grow the therapeutic opportunities in areas such as:
- Cancer types
- Target types
- Internal vs External adenosine targets
11:30 am Panel Discussion – Selecting Combination Partners Rationally
Synopsis
- What types of features should we look for in a potential combination partner for CD73/CD39 inhibitors?
- What can we identify as being a good partner for A2AR and A2B?
- Discuss a methodology that can be used as a process for assessing potential combination partners that improves patient responses and safety profiles
- Postulate what partners have not been tested and suggest reasons why these combinations could hold promise
12:30 pm Lunch Networking Break
Preclinical Modeling In Vivo, In Vitro & Ex Vivo for Confident Clinical Translation of Adenosine Targeted Therapeutics
1:30 pm Novel Tools to Investigate the Role of Adenosine on a Molecular Level Neurologically and/or Oncologically
Synopsis
- Identify new sources of tumor samples that are, or will be, coming online that could aid adenosine researchers
- Discuss protocols and technologies that are useful to help maximize the quantity of insights gained from samples
2:00 pm Preclinical Testing of CD73 or Adora2b Small Molecule Inhibitors in GEM Models of Pancreatic Cancer
Synopsis
- Murine models with high expression of CD73 respond better to CD73 small molecule inhibitors resulting in increased CD8+ T cells
- Targeting the A2B adenosine receptor increases intratumoral CD8+ T cells and may augment the immunomodulating effects of CD73 inhibitors
- GZM+CD8+ T cells in our GEM models expressed high levels of CD73
2:30 pm Afternoon Break & Networking
3:00 pm Spatial Analysis of Immunomodulatory Purinergic Signalling in Cancer Tissue
Synopsis
- Multiplexed tissue imaging provides a means for deeply phenotyping cancer tissues
- Spatially-resolved single-cell analyses can be used to map the interactions between CD73 and CD39 expressing cell types in cancer tissues
- Integrating information from metabolite profiling with mass spectrometry imaging and multiplexed tissue imaging will permit functional characterization of metabolic pathways and their effects on the tumor microenvironment
3:30 pm Panel Discussion – Engineering Better Preclinical Practices for Adenosine Mono & Combo Therapeutic Candidates
Synopsis
- How reproducible is research from 3D organoid models?
- What combinations of experiments offer maximum insights most cost-efficient for both monotherapies and combination therapies?
- How can we better explore hypoxia at the preclinical level?